Recent News

• 03.03.2025 - Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update
• 03.03.2025 - Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update
• 02.19.2025 - Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis
• 02.19.2025 - Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis
• 02.03.2025 - Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
• 02.03.2025 - Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
• 12.03.2024 - Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
• 11.19.2024 - Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis
• 11.14.2024 - Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
• 11.14.2024 - Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Recent Filings

• 03.03.2025 - EX-99.1 EX-99.1
• 03.03.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.19.2025 - EX-99.1 EX-99.1
• 02.19.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.10.2024 - EFFECT Notice of Effectiveness
• 12.02.2024 - POS AM Post-Effective amendments for registration statement
• 11.29.2024 - SC 13D/A General Statement of Acquisition of Beneficial Ownership
• 11.21.2024 - SC 13G Statement of Beneficial Ownership by Certain Investors
• 11.18.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.15.2024 - 424B5 Prospectus [Rule 424(b)(5)]